Our DNA/RNA Base Modification Services support biotech companies, pharmaceutical discovery teams, CROs, diagnostic developers, and academic researchers that need custom oligonucleotides with precisely selected nucleobase changes. Base modifications can be used to tune hybridization behavior, enzymatic recognition, fluorescence response, crosslinking performance, translation-related properties, or biomolecular interaction studies, but successful projects depend on more than simply choosing a modified monomer. Sequence context, modification position, compatibility with synthesis chemistry, purification strategy, and downstream assay conditions all influence whether a base-modified construct will perform as intended.
We provide integrated support spanning modification selection, sequence review, custom DNA and RNA synthesis, site-specific incorporation, multi-site modification planning, analytical characterization, and application-focused technical guidance. Whether your project involves epigenetic standards, modified probes, crosslinking oligos, fluorescent base analogs, or research-stage modified RNA constructs, our team develops fit-for-purpose workflows that balance chemical feasibility, material quality, and experimental usability.
Modification Selection: Customers often know the biological question they want to study, but not which modified base is most suitable. We help compare options such as methylated bases, pseudouridine-family substitutions, inosine, fluorescent base analogs, or reactive photo-crosslinking bases according to the intended readout, target class, and required oligonucleotide format.
Position-Specific Design: A base modification that works at one site may fail at another because of local sequence context, duplex geometry, or enzyme recognition requirements. Our design review focuses on where the modification should be placed, how many modified positions are practical, and whether control sequences are needed to separate chemistry effects from sequence effects.
Chemistry Compatibility: Modified bases do not all behave the same during synthesis, deprotection, purification, or storage. We assess monomer availability, protecting-group logic, compatibility with standard or adapted solid-phase workflows, and the impact of modification density on crude quality, recovery, and scale selection.
Analytical Confirmation: For many programs, it is not enough to confirm only the full-length mass. Teams also need confidence that the intended base modification was incorporated at the right position and that the final material is suitable for the planned assay. We support analytical strategies aligned with sequence complexity, modification type, and reporting expectations.
Application Transfer: Base-modified oligos frequently need to move into probe development, epitranscriptomics workflows, or broader DNA/RNA modification services programs. We help align the modified construct with hybridization conditions, transcription workflows, binding studies, or assay platform constraints so the delivered material is easier to use in practice.
Our service platform is built for teams that need more than catalog ordering. We support custom base-modified DNA and RNA projects from early design review through synthesis, purification, analytical verification, and application-facing documentation.
By integrating nucleic acid chemistry planning with project-specific technical support, we help reduce rework when modified bases must be combined with sequence constraints, scale targets, labeling requirements, or specialized downstream assays.
This table is designed to help project teams compare major classes of base modifications by purpose, common examples, practical use context, and development considerations before sequence finalization.
| Modification Class | Representative Examples | Typical Project Goal | Common DNA/RNA Formats | Key Service Considerations |
| Epigenetic / Native-Like Bases | 5-methylcytidine, N6-methyladenosine, N1-methyladenosine, 5-methyluridine | Build biologically relevant standards or study how native-style base changes affect recognition and function | DNA probes, RNA oligos, reference standards, comparator panels | Position-specific incorporation, matched controls, and analytical confirmation are usually essential |
| Pseudouridine-Family Bases | Pseudouridine, N1-methylpseudouridine | Evaluate RNA structure, translation-related performance, or immunologically differentiated RNA research constructs | Modified RNA oligos, IVT-aligned research projects, RNA fragments | Base choice should be coordinated with the intended workflow, analytical plan, and control set |
| Editing / Wobble Bases | Inosine and related ambiguity-tolerant designs | Explore RNA editing questions, altered pairing behavior, or broadened target recognition | RNA standards, hybridization probes, exploratory design panels | Pairing behavior and interpretation strategy should be reviewed before synthesis |
| Photoactive / Crosslinking Bases | 4-thiouridine, 6-thioguanosine, 5-bromouridine | Capture interactions, enable photocrosslinking, or probe binding interfaces | RNA interaction probes, mechanistic study oligos, assay reagents | Light sensitivity, handling conditions, and assay timing can affect project success |
| Fluorescent Base Analogs | 2-aminopurine, pyrrolo-dC and comparable reporter bases | Monitor local structure, hybridization events, or conformational change without relying only on terminal labels | DNA/RNA probes, folding studies, kinetic assays | Signal behavior depends strongly on local sequence environment and probe architecture |
| Reactive Handle Bases | Amino-allyl, alkyne-bearing, azide-compatible, or other derivatizable base analogs | Create post-synthetic attachment points for dyes, affinity tags, or specialized conjugates | Custom probes, capture oligos, multifunctional research constructs | Conjugation plan, steric effects, and purification route should be defined early |
| Base Modifications | Short Code | Description | Price |
| 1-Methyl-guanosine | m1G | 1-methyl-guanosine is guanosine substituted with a methyl group at position N-1. It has a role as a metabolite. | Inquiry |
| 2,6-Diaminopurine | DAP | One of a number of organic compounds with a purine-like structure with antiviral and antitumor properties. | Inquiry |
| 2-Methyl-adenosine | m2A | A methyl adenosine in which the methyl group is located at position 2 on the adenine ring. | Inquiry |
| 2-Aminopurine | 2AP | The parent compound of 2-aminopurine, comprising a purine core with an amino substituent at the 2-position. It has antimetabolite properties. | Inquiry |
| 4-Thio-uridine | 4-S-U | A mercapturidine and nucleoside analogue. It has an affinity label and anti-metabolite effect. | Inquiry |
| 5-Bromo-Uridine | U[5Br] | 5-Bromo-Uridine is a uridine having a bromo substituent at the 5-position. It has a role as a mutagen. | Inquiry |
| 5-Fluoro-cytidine | C[5F] | 5-Fluoro-cytidine is an organofluorine compound and a member of cytidines. | Inquiry |
| 5-Fluoro-uridine | U[5F] | 5-Fluoro-uridine is an organofluorine compound that is uridine bearing a fluoro substituent at position 5 on the uracil ring. It has a role as a mutagen. | Inquiry |
| 5-Iodo-uridine | U[5I] | An analog of iodinated thymidine. | Inquiry |
| 5-Methyl-cytidine | 5-M-C | 5-Methyl-cytidine is a methylcytidine. | Inquiry |
| 5-Methyl-Deoxycytidine | 5-M-dC | 5-Methyl-Deoxycytidine is a dinucleotide. | Inquiry |
| 5-Methyl-uridine | rT | 5-Methyl-uridine is a natural product found in Ctenodiscus crispatus, Brassica napus, and other organisms with data available. | Inquiry |
| Inosine | I | Inosine is a purine nucleoside in which hypoxanthine is attached to ribofuranose via a beta-N(9)-glycosidic bond. | Inquiry |
| N2-Methyl-guanosine | m2G | N2-Methyl-guanosine is guanosine with the hydrogen on the amine at position N-2 substituted with a methyl group. | Inquiry |
| N3-Methyl-uridine | 3-M-U | N3-Methyl-uridine is a pyrimidine nucleoside. | Inquiry |
| N6,N6-Dimethyl-adenosine | DMA | N6,N6-Dimethyl-adenosine is a methyladenosine compound with two methyl groups attached to N(6) of the adenine nucleobase. | Inquiry |
| N6-Methyl-adenosine | m6A | N6-Methyl-adenosine is an abundant modification of mRNA and DNA and is found in several viruses, and most eukaryotes. | Inquiry |
| O6-Methyl-guanosine | O6mG | O6-Methyl-guanosine is a derivative of the nucleobase guanine. | Inquiry |
| Pseudouridine | ~U | Pseudouridine is the C-glycosyl isomer of the nucleoside uridine. It has a role as an essential metabolite. | Inquiry |
| Purine ribonucleoside | Pu | Purine nucleoside is a natural product. | Inquiry |
| Pyrrolo-cytidine | pC | Modified RNA base. | Inquiry |
| 1-Ribosyltriazole | RBV | A 1-ribosyltriazole that is the 1-ribofuranosyl derivative of 1,2,4-triazole-3-carboxamide. It is a purine analogue. | Inquiry |
Base-modified projects are most successful when chemistry decisions, assay logic, and quality expectations are aligned before synthesis begins. The matrix below summarizes the planning elements we review to reduce avoidable redesign cycles.
| Planning Category | What We Evaluate | Why It Matters | Typical Deliverables | Project Stage |
| Target and Site Review | Intended target region, modified position, neighboring sequence, and comparator design | Prevents choosing a chemically valid modification that does not answer the biological or assay question | Sequence recommendations, control logic, modification placement notes | Discovery |
| Monomer / Nucleotide Selection | Appropriate modified amidite or nucleotide class for DNA, RNA, or related research constructs | Determines whether the requested change is compatible with the chosen synthesis route | Feasibility assessment, build strategy, alternative chemistry options | Discovery |
| Synthesis Feasibility | Sequence length, modification density, base composition, protecting-group compatibility, and expected crude complexity | Helps set realistic scale, turnaround, and purity expectations for challenging constructs | Synthesis plan, scale recommendation, risk flags | Discovery / Early Development |
| Purification Strategy | Whether desalting, cartridge cleanup, PAGE, or HPLC-type purification is most appropriate for the final use | Purification choice affects usable recovery, impurity profile, and downstream reproducibility | Purification recommendation, expected output format, handling guidance | Early Development |
| Analytical Confirmation | Identity confirmation, purity review, and modification-aware characterization planning | Reduces uncertainty when multiple modified positions or unusual base chemistries are involved | Analytical summary, chromatograms, mass data, review notes | Development |
| Application Fit Review | Hybridization conditions, crosslinking setup, binding assay design, transcription workflow, or probe readout requirements | Ensures the final construct is easier to translate into the customer's real experimental workflow | Use guidance, design adjustments, optional follow-on support | Development |
Our workflow is designed for research and diagnostic projects that require technically sound selection, synthesis, purification, and verification of base-modified oligonucleotides.
We review your target sequence, intended application, preferred modification type, quantity needs, and expected analytical package. This step helps distinguish whether the project is best served by a single custom oligo, a control panel, a probe set, or a broader modification-screening strategy.
Our team evaluates base choice, site placement, sequence context, and any interaction with labels, spacers, or adjacent modifications. The outcome is a fit-for-purpose design plan with practical feasibility guidance before synthesis begins.
We finalize the build strategy according to DNA or RNA format, modified monomer requirements, modification count, purification target, and scale. For more demanding constructs, we define contingency options early to reduce redesign risk.
Oligonucleotides are synthesized using appropriate solid-phase chemistry or aligned modified-nucleotide workflows, then purified according to the agreed project objective. Purification is selected to balance material recovery with the purity required for the intended assay.
Identity and purity are reviewed using the analytical package suited to the construct. Where necessary, we pay special attention to modification-heavy sequences or difficult interpretation cases so customers receive data that supports technical decision-making rather than generic shipment confirmation.
Materials are delivered with the agreed documentation, along with handling notes and any relevant design or application comments. Follow-on support can cover matched controls, expanded modification sets, redesign work, or transition into related oligonucleotide programs.
Base-modified oligonucleotide projects are often delayed by fragmented sourcing, incomplete design review, or unclear feasibility assumptions. Our platform is built to give customers technically grounded support from modification concept through material delivery.
DNA and RNA base modifications are widely used in research programs that require more precise control over recognition, structure, signal, or biochemical behavior than standard oligonucleotides can provide. Our services support practical translation of these designs into usable materials.
Whether you need a single site-specific modified oligo, a multi-position comparator panel, a modified RNA construct, or a broader base engineering program, our team can help translate your sequence idea into a workable development plan. We support customers in research, diagnostics, and platform development with technical guidance covering modification selection, synthesis feasibility, purification planning, and analytical review. If your project involves custom DNA, custom RNA, assay-ready probes, epitranscriptomic controls, or modification-heavy sequences that require careful planning, contact us to discuss the most appropriate DNA/RNA base modification workflow for your objectives.
RNA base modification involves chemical changes to RNA bases, such as methylation or acetylation, which can impact RNA function, stability, and interaction with other molecules. These modifications are crucial for understanding RNA structure and its role in gene regulation.
RNA base modifications, such as 5-methylcytidine or pseudouridine, increase RNA stability by making it more resistant to enzymatic degradation. This enhanced stability is important for RNA-based research, including gene expression studies and synthetic biology.
RNA base modifications are used in various applications, including gene silencing, RNA interference (RNAi), and CRISPR-based technologies. They also play a critical role in improving the performance of RNA aptamers and antisense oligonucleotides.
Pseudouridine (Ψ) is a modified base that enhances RNA stability and translation efficiency. Its incorporation into RNA molecules can improve the accuracy of protein synthesis and reduce immune system recognition in RNA-based therapies.
2'-O-methylation is a common RNA modification that enhances RNA stability and prevents degradation by ribonucleases. It is often used in antisense and siRNA research to improve the efficacy and durability of RNA molecules.
Loading ......
